• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

AEE-788 Drug Record

  • Summary
  • Interactions
  • Claims
  • AEE-788 chembl:CHEMBL587723 Antineoplastic

    Alternate Names:

    NVP-AEE-788
    AEE-788
    AEE788
    NVP-AEE788
    GNF-PF-5343
    AEE 788

    Drug Info:

    Drug Class Kinase Inhibitors
    (2 More Sources)

    Publications:

    Kancha et al., 2011, Differential sensitivity of ERBB2 kinase domain mutations towards lapatinib., PLoS ONE
    Kancha et al., 2009, Functional analysis of epidermal growth factor receptor (EGFR) mutations and potential implications for EGFR targeted therapy., Clin. Cancer Res.
  • AEE-788   ERBB2

    Interaction Score: 0.26

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Indication/Tumor Type Advanced Solid Tumor
    Response Type sensitive
    Approval Status Preclinical

    PMIDs:
    22046346


    Sources:
    JAX-CKB MyCancerGenome GuideToPharmacology ChemblInteractions

  • AEE-788   EGFR

    Interaction Score: 0.22

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Indication/Tumor Type Advanced Solid Tumor
    Response Type resistant
    Approval Status Preclinical

    PMIDs:
    19147750


    Sources:
    JAX-CKB MyCancerGenome GuideToPharmacology ChemblInteractions

  • AEE-788   ERBB4

    Interaction Score: 0.2

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Direct Interaction? False
    Endogenous Drug? False
    Specific Action of the Ligand Inhibition

    PMIDs:
    None found


    Sources:
    GuideToPharmacology

  • AEE-788   KDR

    Interaction Score: 0.16

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Specific Action of the Ligand Inhibition
    Endogenous Drug? False
    Direct Interaction? False

    PMIDs:
    None found


    Sources:
    MyCancerGenome GuideToPharmacology ChemblInteractions

  • AEE-788   FGFR2

    Interaction Score: 0.15

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    TTD

  • AEE-788   FGFR3

    Interaction Score: 0.13

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    TTD

  • AEE-788   FLT1

    Interaction Score: 0.09

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction Vascular endothelial growth factor receptor 1 inhibitor
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • MyCancerGenome: AEE788

    • Version: 20-Jun-2017

    Alternate Names:
    NVP-AEE788 Development Name

    Drug Info:
    Drug Class Kinase Inhibitors

    Publications:

  • JAX-CKB: AEE788

    • Version: 27-September-2017

    Alternate Names:

    Drug Info:

    Publications:
    Kancha et al., 2011, Differential sensitivity of ERBB2 kinase domain mutations towards lapatinib., PLoS ONE
    Kancha et al., 2009, Functional analysis of epidermal growth factor receptor (EGFR) mutations and potential implications for EGFR targeted therapy., Clin. Cancer Res.

  • TTD: AEE-788

    • Version: 2020.06.01

    Alternate Names:
    D0G2QH TTD Drug ID

    Drug Info:

    Publications:

  • ChemblDrugs: chembl:CHEMBL587723

    • Version: ChEMBL_27

    Alternate Names:

    Drug Info:

    Publications:

  • ChemblInteractions: CHEMBL587723

    • Version: chembl_23

    Alternate Names:

    Drug Info:

    Publications:

  • GuideToPharmacology: 223365978

    • Version: 29-September-2020

    Alternate Names:

    Drug Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21